Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance
Justin R. Bailey, … , Steven K.H. Foung, Stuart C. Ray
Justin R. Bailey, … , Steven K.H. Foung, Stuart C. Ray
Published December 15, 2014
Citation Information: J Clin Invest. 2015;125(1):437-447. https://doi.org/10.1172/JCI78794.
View: Text | PDF
Research Article

Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance

  • Text
  • PDF
Abstract

For hepatitis C virus (HCV) and other highly variable viruses, broadly neutralizing mAbs are an important guide for vaccine development. The development of resistance to anti-HCV mAbs is poorly understood, in part due to a lack of neutralization testing against diverse, representative panels of HCV variants. Here, we developed a neutralization panel expressing diverse, naturally occurring HCV envelopes (E1E2s) and used this panel to characterize neutralizing breadth and resistance mechanisms of 18 previously described broadly neutralizing anti-HCV human mAbs. The observed mAb resistance could not be attributed to polymorphisms in E1E2 at known mAb-binding residues. Additionally, hierarchical clustering analysis of neutralization resistance patterns revealed relationships between mAbs that were not predicted by prior epitope mapping, identifying 3 distinct neutralization clusters. Using this clustering analysis and envelope sequence data, we identified polymorphisms in E2 that confer resistance to multiple broadly neutralizing mAbs. These polymorphisms, which are not at mAb contact residues, also conferred resistance to neutralization by plasma from HCV-infected subjects. Together, our method of neutralization clustering with sequence analysis reveals that polymorphisms at noncontact residues may be a major immune evasion mechanism for HCV, facilitating viral persistence and presenting a challenge for HCV vaccine development.

Authors

Justin R. Bailey, Lisa N. Wasilewski, Anna E. Snider, Ramy El-Diwany, William O. Osburn, Zhenyong Keck, Steven K.H. Foung, Stuart C. Ray

×

Figure 1

Ranking of library HCVpp resistance reveals relationships among mAbs.

Options: View larger image (or click on image) Download as PowerPoint
Ranking of library HCVpp resistance reveals relationships among mAbs.
(A...
(A) Each bar represents neutralization of a unique HCVpp by the indicated mAb. Representative mAbs are shown here, and neutralization results for all 18 mAbs are shown in Supplemental Figure 1. Relative infection is infection in the presence of 10 μg/ml neutralizing mAb relative to infection in the presence of nonspecific IgG. Error bars indicate SDs between duplicate wells. Pseudoparticles with murine leukemia virus (MLV) envelope serve as a negative control for neutralization. (B–D) Each blue diamond indicates neutralization of an individual pseudoparticle by one antibody on the x axis and a second antibody on the y axis. Spearman correlations (r) are indicated for each mAb pair. *P < 0.0001. (B) Comparison of HCVpp resistance to HC33.4 and HC33.8, 2 closely related mAbs targeting the same linear epitope. (C) Comparison of HCVpp resistance to 2 unrelated mAbs, HC33.4 and HC84.22. (D) Comparison of HCVpp resistance to AR3C and HC84.22, 2 mAbs with distinct epitopes based on alanine scanning but overlapping epitopes based on crystal structures.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts